Replies to post #23839 on $Bob's and Jbem's Bitchin' Bios

[buckiii2]

OUT NOW!

http://oncosec.com/wp-content/uploads/2017/11/ONCS-SITC-POSTER-2017_-1.pdf

[buckiii2]

Title: Clinical and biomarker analyses of a phase II study of intratumoral tavokinogene telseplasmid (pIL-12) plus pembrolizumab in stage III/IV melanoma patients predicted to not respond to anti-PD-1

Poster Number: P524

Lead Author: Alain Algazi, MD, Associate Professor, Department of Medicine (Hematology/Oncology), UCSF

Date and Time: Saturday, November 11th, 12:30-2:00 p.m. and 6:30-8:00 p.m.